#ASCO14 - Poster: Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Karim Fizazi, Robert Jones, Stephane Oudard, Eleni Efstathiou, Fred Saad, Ronald De Wit, Johann Sebastian De Bono, Felipe Cruz, George Fountzilas, Albertas Ulys, Flavio Carcano, Neeraj Agarwal, David B. Agus, Joaquim Bellmunt, Daniel Peter Petrylak, Connie Lee, Bindu Tejura, Niels Geert Borgstein, and Robert Dreicer at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

 asco 2014 fizazi poster 5042 thumb

Institut Gustave Roussy, University of Paris Sud, Villejuif, France; University of Glasgow, Institute of Cancer Sciences, Glasgow, United Kingdom; HEGP, Paris, Université Paris Descartes, Paris, France; Alexandra General Hospital of Athens, Oncology Department, Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece; University of Montréal Hospital Center, Montréal, QC, Canada; Erasmus University Medical Center, Rotterdam, Netherlands; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; ABC Foundation School of Medicine, Santo André, Brazil; Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Hospital de Cancer de Barretos, Barretos-SP, Brazil; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; University of Southern California, Los Angeles, CA; Dana-Farber Cancer Center Institute/Brigham and Women's Cancer Center, Boston, MA; Columbia University Medical Center, New York, NY; Takeda Pharmaceuticals International Co., Cambridge, MA; Cleveland Clinic, Cleveland, OH